Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 5OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

Imatinib Mesylate 10Cytarabine 7Cyclosporine 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Dasatinib 4Tacrolimus 3Interferon-alpha 3Idarubicin 3Hydroxyurea 3Busulfan 3tipifarnib 2fludarabine 2belinostat 2Radiotherapy 2Mycophenolic Acid 2Ipilimumab 2Homoharringtonine 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Decitabine 2CTLA-4 Antigen 2Bortezomib 2veliparib 1temsirolimus 1tanespimycin 1sargramostim 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Homoharringtonine × Clear all
NCT00003694 2013-06-05

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00006364 2013-01-23

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡